Source comparison
Difference Between CJC-1295 No DAC & Ipamorelin and Sermorelin: Clinical Comparison
| Peptide | Receptor Target | Half-Life | Typical Dosing | GH Release Pattern | Cortisol/Prolactin Effect | Bottom Line ||—|—|—|—|—|—|| CJC-1295 no DAC | GHRH receptor (GHRHR) on pituitary somatotrophs | 6–8 hours | 100–200 mcg, 2–3× weekly | Amplifies natural
This comparison does not assign a generated winner or score.
- | Peptide | Receptor Target | Half-Life | Typical Dosing | GH Release Pattern | Cortisol/Prolactin Effect | Bottom Line ||—|—|—|—|—|—|| CJC-1295 no DAC | GHRH receptor (GHRHR) on pituitary somatotrophs | 6–8 hours | 100–200 mcg, 2–3× weekly | Amplifies natural GH pulses without creating sustained elevation | None. Preserves physiological feedback | Best for sustained pulse amplification with minimal injection frequency || Ipamorelin | Ghrelin receptor (GHSR-1a) on pituitary somatotrophs | ~2 hours | 200–300 mcg, 1–3× daily | Produces discrete GH secretory bursts on-demand | None. Highly selective for GH pathway only | Best for targeted GH release with zero secondary hormone activation || Sermorelin | GHRH receptor (GHRHR) on pituitary somatotrophs | 10–20 minutes | 200–500 mcg daily, pre-sleep | Mirrors natural hypothalamic GH rhythm but clears rapidly | None. Regulated by somatostatin feedback | Best for researchers prioritising physiological mimicry over convenience || CJC-1295 + Ipa
- The comparison clarifies why combination protocols dominate research use: CJC-1295 no DAC extends efficacy windows, Ipamorelin adds selective on-demand release, and neither elevates cortisol or prolactin. The two hormonal side effects that made older secretagogues like GHRP-6 problematic for long-term studies.